NT-pro brain natriuretic peptide levels and the risk of death in the cooperative study of sickle cell disease

British Journal of Haematology

Volumn 154, Issue 4, 2011, Pages 512-520

  Machado, Roberto F ^a   Hildesheim, Mariana ^b,c   Mendelsohn, Laurel ^b,c   Remaley, Alan T ^c   Kato, Gregory J ^b,c   Gladwin, Mark T ^d,e  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

^c NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

^d UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^e UNIVERSITY OF PITTSBURGH   (United States)

Author keywords

Biomarkers; Brain natriuretic peptide; Pulmonary hypertension; Sickle cell disease; Survival

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; BILIRUBIN; HEMOGLOBIN; LACTATE DEHYDROGENASE;

ADULT; ARTICLE; CHILD; CONTROLLED STUDY; FEMALE; HEMOLYTIC ANEMIA; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; MORTALITY; PREDICTION; PREVALENCE; PRIORITY JOURNAL; PULMONARY HYPERTENSION; RISK ASSESSMENT; SICKLE CELL ANEMIA;

ADULT; AGE DISTRIBUTION; ANEMIA, HEMOLYTIC; ANEMIA, SICKLE CELL; BIOLOGICAL MARKERS; CHILD; CHILD, PRESCHOOL; EPIDEMIOLOGIC METHODS; FEMALE; HUMANS; HYPERTENSION, PULMONARY; MALE; NATRIURETIC PEPTIDE, BRAIN; PEPTIDE FRAGMENTS; PROGNOSIS; UNITED STATES;

EID: 79960845387     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/j.1365-2141.2011.08777.x     Document Type: Article

References (48)

1. Albers, S., Mir, T.S., Haddad, M. & Laer, S. (2006) N-Terminal pro-brain natriuretic peptide: normal ranges in the pediatric population including method comparison and interlaboratory variability. Clinical Chemistry and Laboratory Medicine, 44, 80-85.
2. Anthi, A., Machado, R.F., Jison, M.L., Taveira-Dasilva, A.M., Rubin, L.J., Hunter, L., Hunter, C.J., Coles, W., Nichols, J., Avila, N.A., Sachdev, V., Chen, C.C. & Gladwin, M.T. (2007) Hemodynamic and functional assessment of patients with sickle cell disease and pulmonary hypertension. American Journal of Respiratory and Critical Care Medicine, 175, 1272-1279.
3. Ataga, K., Jones, S., Olajide, O., Strayhorn, D., Lail, A. & Orringer, E.P. (2004) The relationship of pulmonary hypertension and survival in sickle cell disease. Blood, 104, 463a.
4. Ataga, K.I., Moore, C.G., Jones, S., Olajide, O., Strayhorn, D., Hinderliter, A. & Orringer, E.P. (2006) Pulmonary hypertension in patients with sickle cell disease: a longitudinal study. British Journal of Haematology, 134, 109-115.
5. Bunn, H.F., Nathan, D.G., Dover, G.J., Hebbel, R.P., Platt, O.S., Rosse, W.F. & Ware, R.E. (2010) Pulmonary hypertension and nitric oxide depletion in sickle cell disease. Blood, 116, 687-692.
6. Cox, D.R. & Snell, E.J. (1989) The Analysis of Binary Data. Chapman and Hall, London.
7. Dasgupta, T., Fabry, M.E. & Kaul, D.K. (2010) Antisickling property of fetal hemoglobin enhances nitric oxide bioavailability and ameliorates organ oxidative stress in transgenic-knockout sickle mice. American Journal of Physiology: Regulatory, Integrative and Comparative Physiology, 298, R394-R402.
8. De Castro, L.M., Jonassaint, J.C., Graham, F.L., Ashley-Koch, A. & Telen, M.J. (2008) Pulmonary hypertension associated with sickle cell disease: clinical and laboratory endpoints and disease outcomes. American Journal of Hematology, 83, 19-25.
9. Di Angelantonio, E., Chowdhury, R., Sarwar, N., Ray, K.K., Gobin, R., Saleheen, D., Thompson, A., Gudnason, V., Sattar, N. & Danesh, J. (2009) B-type natriuretic peptides and cardiovascular risk: systematic review and meta-analysis of 40 prospective studies. Circulation, 120, 2177-2187.
10. Frei, A.C., Guo, Y., Jones, D.W., Pritchard, Jr, K.A., Fagan, K.A., Hogg, N. & Wandersee, N.J. (2008) Vascular dysfunction in a murine model of severe hemolysis. Blood, 112, 398-405.
11. Gaston, M. & Rosse, W.F. (1982) The cooperative study of sickle cell disease: review of study design and objectives. The American Journal of Pediatric Hematology/Oncology, 4, 197-201.
12. Gill, F.M., Sleeper, L.A., Weiner, S.J., Brown, A.K., Bellevue, R., Grover, R., Pegelow, C.H. & Vichinsky, E. (1995) Clinical events in the first decade in a cohort of infants with sickle cell disease. Cooperative Study of Sickle Cell Disease. Blood, 86, 776-783.
13. Gladwin, M.T., Sachdev, V., Jison, M.L., Shizukuda, Y., Plehn, J.F., Minter, K., Brown, B., Coles, W.A., Nichols, J.S., Ernst, I., Hunter, L.A., Blackwelder, W.C., Schechter, A.N., Rodgers, G.P., Castro, O. & Ognibene, F.P. (2004) Pulmonary hypertension as a risk factor for death in patients with sickle cell disease. New England Journal of Medicine, 350, 886-895.
14. Hall, C. (2004) Essential biochemistry and physiology of (NT-pro)BNP. European Journal of Heart Failure, 6, 257-260.
15. Hill, A., Rother, R.P., Wang, X., Morris, Jr, S.M., Quinn-Senger, K., Kelly, R., Richards, S.J., Bessler, M., Bell, L., Hillmen, P. & Gladwin, M.T. (2010) Effect of eculizumab on haemolysis-associated nitric oxide depletion, dyspnoea, and measures of pulmonary hypertension in patients with paroxysmal nocturnal haemoglobinuria. British Journal of Haematology, 149, 414-425.
16. Hosmer, D.W. & Lemeshow, S. (1989) Applied Logistic Regression. John Wiley & Sons, New York.
17. Hsu, L.L., Champion, H.C., Campbell-Lee, S.A., Bivalacqua, T.J., Manci, E.A., Diwan, B.A., Schimel, D.M., Cochard, A.E., Wang, X., Schechter, A.N., Noguchi, C.T. & Gladwin, M.T. (2007) Hemolysis in sickle cell mice causes pulmonary hypertension due to global impairment in nitric oxide bioavailability. Blood, 109, 3088-3098.
18. Kato, G.J., McGowan, V., Machado, R.F., Little, J.A., Taylor, J.t., Morris, C.R., Nichols, J.S., Wang, X., Poljakovic, M., Morris, Jr, S.M. & Gladwin, M.T. (2006) Lactate dehydrogenase as a biomarker of hemolysis-associated nitric oxide resistance, priapism, leg ulceration, pulmonary hypertension, and death in patients with sickle cell disease. Blood, 107, 2279-2285.
19. Kaul, D.K., Liu, X.D., Chang, H.Y., Nagel, R.L. & Fabry, M.E. (2004) Effect of fetal hemoglobin on microvascular regulation in sickle transgenic-knockout mice. Journal of Clinical Investigation, 114, 1136-1145.
20. Koch, A. & Singer, H. (2003) Normal values of B type natriuretic peptide in infants, children, and adolescents. Heart, 89, 875-878.
21. Koch, A.M., Rauh, M., Zink, S. & Singer, H. (2006) Decreasing ratio of plasma N-terminal pro-B-type natriuretic peptide and B-type natriuretic peptide according to age. Acta Paediatrica, 95, 805-809.
22. Kragelund, C., Gronning, B., Kober, L., Hildebrandt, P. & Steffensen, R. (2005) N-terminal pro-B-type natriuretic peptide and long-term mortality in stable coronary heart disease. New England Journal of Medicine, 352, 666-675.
23. Lee, A., Thomas, P., Cupidore, L., Serjeant, B. & Serjeant, G. (1995) Improved survival in homozygous sickle cell disease: lessons from a cohort study. BMJ, 311, 1600-1602.
24. Levin, E.R., Gardner, D.G. & Samson, W.K. (1998) Natriuretic peptides. New England Journal of Medicine, 339, 321-328.
25. Machado, R.F., Anthi, A., Steinberg, M.H., Bonds, D., Sachdev, V., Kato, G.J., Taveira-DaSilva, A.M., Ballas, S.K., Blackwelder, W., Xu, X., Hunter, L., Barton, B., Waclawiw, M., Castro, O. & Gladwin, M.T. (2006) N-terminal pro-brain natriuretic peptide levels and risk of death in sickle cell disease. JAMA, 296, 310-318.
26. Magge, L. (1990) Measures based on wald and likelihood ratio joint significance tests. American Statistician, 44, 250-253.
27. Meyer, C., Heiss, C., Drexhage, C., Kehmeier, E.S., Balzer, J., Muhlfeld, A., Merx, M.W., Lauer, T., Kuhl, H., Floege, J., Kelm, M. & Rassaf, T. (2010) Hemodialysis-induced release of hemoglobin limits nitric oxide bioavailability and impairs vascular function. Journal of the American College of Cardiology, 55, 454-459.
28. Minniti, C.P., Sable, C., Campbell, A., Rana, S., Ensing, G., Dham, N., Onyekwere, O., Nouraie, M., Kato, G.J., Gladwin, M.T., Castro, O.L. & Gordeuk, V.R. (2009) Elevated tricuspid regurgitant jet velocity in children and adolescents with sickle cell disease: association with hemolysis and hemoglobin oxygen desaturation. Haematologica, 94, 340-347.
29. Mir, T.S., Marohn, S., Laer, S., Eiselt, M., Grollmus, O. & Weil, J. (2002) Plasma concentrations of N-terminal pro-brain natriuretic peptide in control children from the neonatal to adolescent period and in children with congestive heart failure. Pediatrics, 110, e76.
30. Mir, T.S., Flato, M., Falkenberg, J., Haddad, M., Budden, R., Weil, J., Albers, S. & Laer, S. (2006) Plasma concentrations of N-terminal brain natriuretic peptide in healthy children, adolescents, and young adults: effect of age and gender. Pediatric Cardiology, 27, 73-77.
31. Nagelkerke, N.J. (1991) A note on a general definition of the coefficient of determination. Biometrika, 78, 691-692.
32. Naoman, S.G., Nouraie, M., Castro, O.L., Nwokolo, C., Fadojutimi-Akinsiku, M., Diaz, S., Willie-Carnegie, G., Andrews, N. & Gordeuk, V.R. (2009) Echocardiographic findings in patients with sickle cell disease. Annals of Hematology, 89, 61-66.
33. Nir, A., Lindinger, A., Rauh, M., Bar-Oz, B., Laer, S., Schwachtgen, L., Koch, A., Falkenberg, J. & Mir, T.S. (2009) NT-pro-B-type natriuretic peptide in infants and children: reference values based on combined data from four studies. Pediatric Cardiology, 30, 3-8.
34. Nolan, V.G., Wyszynski, D.F., Farrer, L.A. & Steinberg, M.H. (2005) Hemolysis associated priapism in sickle cell disease. Blood, 106, 3264-3267.
35. Nolan, V.G., Adewoye, A., Baldwin, C., Wang, L., Ma, Q., Wyszynski, D.F., Farrell, J.J., Sebastiani, P., Farrer, L.A. & Steinberg, M.H. (2006) Sickle cell leg ulcers: associations with haemolysis and SNPs in Klotho, TEK and genes of the TGF-beta/BMP pathway. British Journal of Haematology, 133, 570-578.
36. Onyekwere, O.C., Campbell, A., Teshome, M., Onyeagoro, S., Sylvan, C., Akintilo, A., Hutchinson, S., Ensing, G., Gaskin, P., Kato, G., Rana, S., Kwagyan, J., Gordeuk, V., Williams, J. & Castro, O. (2008) Pulmonary hypertension in children and adolescents with sickle cell disease. Pediatric Cardiology, 29, 309-312.
37. Pashankar, F.D., Carbonella, J., Bazzy-Asaad, A. & Friedman, A. (2008) Prevalence and risk factors of elevated pulmonary artery pressures in children with sickle cell disease. Pediatrics, 121, 777-782.
38. Pashankar, F.D., Carbonella, J., Bazzy-Asaad, A. & Friedman, A. (2009) Longitudinal follow up of elevated pulmonary artery pressures in children with sickle cell disease. British Journal of Haematology, 144, 736-741.
39. Platt, O.S., Brambilla, D.J., Rosse, W.F., Milner, P.F., Castro, O., Steinberg, M.H. & Klug, P.P. (1994) Mortality in sickle cell disease. Life expectancy and risk factors for early death. New England Journal of Medicine, 330, 1639-1644.
40. Quinn, C.T., Rogers, Z.R. & Buchanan, G.R. (2004) Survival of children with sickle cell disease. Blood, 103, 4023-4027.
41. Reiter, C.D., Wang, X., Tanus-Santos, J.E., Hogg, N., Cannon, R.O., Schechter, A.N. & Gladwin, M.T. (2002) Cell-free hemoglobin limits nitric oxide bioavailability in sickle-cell disease. Nature Medicine, 8, 1383-1389.
42. Steinberg, M.H., Barton, F., Castro, O., Pegelow, C.H., Ballas, S.K., Kutlar, A., Orringer, E., Bellevue, R., Olivieri, N., Eckman, J., Varma, M., Ramirez, G., Adler, B., Smith, W., Carlos, T., Ataga, K., DeCastro, L., Bigelow, C., Saunthararajah, Y., Telfer, M., Vichinsky, E., Claster, S., Shurin, S., Bridges, K., Waclawiw, M., Bonds, D. & Terrin, M. (2003) Effect of hydroxyurea on mortality and morbidity in adult sickle cell anemia: risks and benefits up to 9years of treatment. JAMA, 289, 1645-1651.
43. Voskaridou, E., Tsetsos, G., Tsoutsias, A., Spyropoulou, E., Christoulas, D. & Terpos, E. (2007) Pulmonary hypertension in patients with sickle cell/beta thalassemia: incidence and correlation with serum N-terminal pro-brain natriuretic peptide concentrations. Haematologica, 92, 738-743.
44. Voskaridou, E., Christoulas, D., Bilalis, A., Plata, E., Varvagiannis, K., Stamatopoulos, G., Sinopoulou, K., Balassopoulou, A., Loukopoulos, D. & Terpos, E. (2010) The effect of prolonged administration of hydroxyurea on morbidity and mortality in adult patients with sickle cell syndromes: results of a 17-year, single-center trial (LaSHS). Blood, 115, 2354-2363.
45. Wang, A.Y. & Lai, K.N. (2008) Use of cardiac biomarkers in end-stage renal disease. Journal of the American Society of Nephrology, 19, 1643-1652.
46. Weatherall, D.J. & Clegg, J.B. (2001) Inherited haemoglobin disorders: an increasing global health problem. Bulletin of the World Health Organization, 79, 704-712.
47. Yeo, T.W., Lampah, D.A., Gitawati, R., Tjitra, E., Kenangalem, E., McNeil, Y.R., Darcy, C.J., Granger, D.L., Weinberg, J.B., Lopansri, B.K., Price, R.N., Duffull, S.B., Celermajer, D.S. & Anstey, N.M. (2007) Impaired nitric oxide bioavailability and l-arginine reversible endothelial dysfunction in adults with falciparum malaria. The Journal of Experimental Medicine, 204, 2693-2704.
48. Yeo, T.W., Lampah, D.A., Tjitra, E., Gitawati, R., Kenangalem, E., Piera, K., Granger, D.L., Lopansri, B.K., Weinberg, J.B., Price, R.N., Duffull, S.B., Celermajer, D.S. & Anstey, N.M. (2009) Relationship of cell-free hemoglobin to impaired endothelial nitric oxide bioavailability and perfusion in severe falciparum malaria. Journal of Infectious Diseases, 200, 1522-1529.